Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.50 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

36 37 Next >

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement ↗

July 23, 2025

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders

July 23, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders

July 23, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours ↗

July 21, 2025

Via Stocktwits

FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division ↗

July 22, 2025

George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and drug advertising rules.

Via Benzinga

Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 22, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 22, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Sarepta Tumbles On The 'Painful' Decision To Stop Selling Elevidys ↗

July 22, 2025

Sarepta stock toppled Tuesday after the company said it would voluntarily stop all shipments of Elevidys.

Via Investor's Business Daily

Topics Death ETFs

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review ↗

July 22, 2025

Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.

Via Benzinga

Agilysys Posts Downbeat Earnings, Joins NXP Semiconductors And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 22, 2025

Via Benzinga

This Lululemon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

July 22, 2025

Via Benzinga

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.

July 21, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets ↗

July 21, 2025

Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty.

Via Benzinga

Sarepta Topples, Again, After Refusing The FDA's Request To Pull Elevidys ↗

July 21, 2025

The company is setting up for a showdown with the FDA over its approved gene therapy, Elevidys.

Via Investor's Business Daily

Topics Death Government

Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)

July 21, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)

July 21, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 21, 2025

Via Benzinga

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗

July 21, 2025

Via Benzinga

Get insights into the top gainers and losers of Monday's pre-market session. ↗

July 21, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline

July 21, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys ↗

July 21, 2025

FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due to safety concerns.

Via Benzinga

Topics Death

GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why ↗

July 20, 2025

GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny.

Via Stocktwits

Topics Death Workforce

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

July 20, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm

July 20, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

July 20, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Sarepta Therapeutics Provides Statement on ELEVIDYS

July 18, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 18, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 18, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 18, 2025

From The Schall Law Firm

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.